News
Media
Conferences
Publications
CME/CE
Resources
Subscribe
About
Partnerships

|Articles|May 1, 2002

Why we shouldn't screen pregnant patients for BV

BV in pregnant patients

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Related Content

FDA accepts extended duration sNDA for copper intrauterine system | Image credit: Contemporary OB/GYN

FDA accepts extended duration sNDA for MIUDELLA IUD

ByJoshua Fitch, Senior Editor

September 14th 2026

Certolizumab pegol's FDA breakthrough designation, atogepant's LUNA results, deep implant removal guidance

Certolizumab pegol's FDA breakthrough designation, atogepant's LUNA results, deep implant removal guidance

ByJoshua Fitch, Senior Editor

September 14th 2026

Amber Watters, MD, on emergency preparedness and building a version program

Amber Watters, MD, on emergency preparedness and building a version program

ByAmber Watters, MD, MS

September 11th 2026

New tool translates pregnancy test research into individualized patient counseling resource

ByAlexandra C. Sundermann, MD, PhD

September 11th 2026

Kevin Ault, MD, on maternal immunization as a bridge to pediatric vaccination

ByKevin Ault, MD

September 11th 2026

Latest CME

Join Us at The Pathology Meeting in Las Vegas

In-Person + Virtual Event

Join Us at The Pathology Meeting in Las Vegas

October 5, 2026

Join Us at The Pathology Meeting in Las Vegas

In-Person + Virtual Event

Join Us at The Pathology Meeting in Las Vegas

October 4-5, 2026

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Case-based Simulation

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Rachel N. Grisham, MD

Trending on Contemporary OB/GYN

Society of Family Planning issues first guidance on deep and nonpalpable contraceptive implant removal

Amber Watters, MD, on emergency preparedness and building a version program

FDA accepts extended duration sNDA for MIUDELLA IUD

Certolizumab pegol's FDA breakthrough designation, atogepant's LUNA results, deep implant removal guidance

New tool translates pregnancy test research into individualized patient counseling resource